Safety Study of MultiGeneAngio in Patients With Peripheral Arterial

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and activity of increasing doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with peripheral arterial disease.

Clinical Trial Description

Approximately 16 million patients worldwide (1 in 20 people over the age of 50) suffer from peripheral arterial disease(PAD). PAD is characterized by narrowing or occlusion of vessels supplying blood to the lower limbs, most often due to atherosclerosis. Symptoms of PAD include claudication that may progress to critical limb ischemia manifested by rest pain, tissue loss and gangrene, which eventually may necessitate amputation.

MultiGeneAngio is a cell therapy-based product developed for treatment of patients with PAD secondary to narrow or blocked arteries in the legs. MultiGeneAngio is composed of endothelial and smooth muscle cells that are isolated from a short vein segment stripped from the patient's arm. After isolation the cells are expanded, characterized, and gene modified by transfer of angiogenic genes.

MultiGeneAngio is a clear cell suspension injected intra-arterially at the site of blockage using a standard diagnostic catheter, in order to create and expand new collateral arteries, and thereby improve blood flow to an ischemic limb.

Comprehensive pre-clinical studies, as well as clinical experience with PAD patients suffering from claudication showed that production and administration of MultiGeneAngio was feasible and safe, as no apparent drug-related adverse events have been observed. Moreover, follow-up data of peak walking times imply a beneficial trend of this efficacy end-point. Additional follow-up data will continue to be collected to help evaluate the safety and efficacy of MultiGeneAngio. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00390767
Study type	Interventional
Source	MultiGene Vascular Systems Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	October 2006
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01359423` - Comparison of Primary Long Full Coverage Stenting vs Primary Short Spot Stenting for Long Femoropopliteal Artery Disease.	N/A
Recruiting	`NCT02389023` - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery	N/A
Completed	`NCT00962897` - Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusion	N/A
Completed	`NCT00693823` - Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusive Disease	N/A
Completed	`NCT02475200` - Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
Completed	`NCT03288181` - Effects of Passive Muscle Stretching on Vascular Function and Symptoms of PAD	N/A
Recruiting	`NCT01450722` - Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery	Phase 3
Completed	`NCT01734603` - Intensive Rehabilitation in Peripheral Arterial Disease With Claudication: Effects of a Treadmill Training With Active Recovery	Phase 3
Recruiting	`NCT01231360` - The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease (PAD)	N/A
Terminated	`NCT01022606` - Intra-arterial Measurement of pO2 in Walking Induced Transient Hack Profiles	Phase 1
Terminated	`NCT01808989` - Clinical Interest of the TcPO2 Technique
Completed	`NCT01858363` - ILLUMENATE EU Randomized Clinical Trial	N/A
Terminated	`NCT01341340` - The ABSORB BTK (Below The Knee) Clinical Investigation	N/A
Completed	`NCT01468974` - ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System	N/A
Completed	`NCT02341664` - Patient and Provider Assessment of Lipid Management Registry
Completed	`NCT04058171` - Validation of a Treadmill Walking Test to Discriminate Neurogenic Claudication From Vascular Claudication
Completed	`NCT02719665` - THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease	N/A
Not yet recruiting	`NCT05712395` - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease	N/A
Not yet recruiting	`NCT03845036` - The Effects of Diet and Exercise Interventions in Peripheral Artery Disease	N/A
Recruiting	`NCT06176898` - Neurostimulation in Intermittent Claudication	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms